GREAT — a randomized aneurysm trial. Design of a randomized controlled multicenter study comparing HydroSoft/HydroFrame and bare platinum coils for endovascular aneurysm treatment

International audienceThe effectiveness of a hybrid hydrogel platinum detachable coil (HydroCoil; MicroVention Inc., Tustin, CA) for endovascular aneurysm treatment has been proven in a recently published RCT. Due to technical restrictions (coil stiffness, time restriction for placement), the HydroSoft coil as well as a corresponding 3D framing coil, the HydroFrame coil (MicroVention Inc., Tustin, CA), a class of new softer coils containing less hydrogel and swelling more slowly than the HydroCoil, have been developed and brought to clinical practice. The present study aims to compare the effectiveness of endovascular aneurysm treatment with coil embolization between patients allocated HydroSoft/HydroFrame versus bare platinum coiling. GREAT is a randomized, controlled, multicentre trial in patients bearing cerebral aneurysms to be treated by coil embolization. Eligible patients were randomized to either coil embolization with HydroSoft/HydroFrame coils (>50 % of administered coil length), or bare platinum coils. Inclusion criteria were as follows: age 18-75, ruptured aneurysm (WFNS 1-3) and unruptured aneurysm with a diameter between 4 and 12 mm. Anatomy such that endovascular coil occlusion deemed possible and willingness of the neurointerventionalist to use either HydroSoft/HydroFrame or bare platinum coils. Exclusion criteria were as follows: aneurysms previously treated by coiling or clipping. Primary endpoint is a composite of major aneurysm recurrence on follow-up angiography and poor clinical outcome (modified Rankin scale 3 or higher), both assessed at 18 months post treatment. Risk differences for poor outcomes will be estimated in a modified intention-to-treat analysis stratified by rupture status (DRKS-ID: DRKS00003132)

Hybrid CoMoS-polyaniline nanowires catalysts for hydrodesulfurisation applications

International audienceCatalytic performances of promoted CoMoS catalysts were greatly improved via a synthesis strategy based on the structuration of the active phase using self-assembled PANI (Polyaniline) nanowires followed by an addition step of cobalt acetylacetonate on oxidic or sulfided Mo-based hybrids. Taking into account the different promotion levels, slabs lengths determined by XPS and TEM, the highest rate constants normalized by mol of (MoS2)edges+corner in the hydrodesulfurization of 3-methylthiophene were obtained when Co(acac)2 is deposited on a MoS3/PANI hybrid precursor. The normalized HDS rate constants for the different samples followed the increase in Co/Moedges+corner atomic ratios whereas an optimum for HDS/HYD selectivity in the same ratio was observed

Cervical arterial abnormalities and outcome after aneurysmal subarachnoid haemorrhage: A pilot cohort study

International audienc

Influence of Pluronic® P123 Addition in the Synthesis of Bulk Ni Promoted MoS2 Catalyst. Application to the Selective Hydrodesulfurization of Sulfur Model Molecules Representative of FCC Gasoline

International audienceA way to improve hydrotreatment processes is to enhance the intrinsic activity of Ni or Co promoted MoS 2 catalysts that are commonly used in such reactions. The aim of this work was to investigate the impact of the presence of Pluronic ® P123 as a structuring agent during the synthesis of Ni promoted MoS 2 catalysts (named NiMoS) in water at room temperature. A series of analyses, i.e., X-ray diffraction (XRD), chemical analysis, inductively coupled plasma mass spectrometry (ICP-MS), nitrogen adsorption-desorption isotherms, transmission electron microscopy (TEM) and X-ray photoelectron spectroscopy (XPS), helped in characterizing the NiMoS-P123 and NiMoS catalysts, the latter being prepared in the absence of polymer. Both compounds contained MoS 2 phase (~85 atomic% considering Mo atoms), a similar amount of mixed Ni-Mo-S phase (40-50% considering Ni) and some amount of NiS and Ni-oxidized impurity phases. The main differences between the two catalysts were a much larger specific surface area (126 m 2 ·g −1 instead of 31 m 2 ·g −1) and a better dispersion of the active phase as shown by the lower slab stacking (2.7 instead of 4.8) for NiMoS-P123, and the presence of C in NiMoS-P123 (9.4 wt.% instead of 0.6 wt.%), indicating an incomplete decomposition of the polymer during thermal treatment. Thanks to its larger specific surface area and lower slab stacking and therefore modification of active Mo site properties, the compound prepared in the presence of Pluronic ® P123 exhibits a strong increase of the catalytic activity expressed per Mo atom for the transformation of 3-methylthiophene. Such improvement in catalytic activity was not observed for the transformation of benzothiophene likely due to poisonous residual carbon which results from the presence of Pluronic ® P123 during the synthesis

Second-Generation Hydrogel Coils for the Endovascular Treatment of Intracranial Aneurysms: A Randomized Controlled Trial

BACKGROUND AND PURPOSE: Endovascular embolization of intracranial aneurysms with hydrogel-coated coils lowers the risk of major recurrence, but technical limitations (coil stiffness and time restriction for placement) have prevented their wider clinical use. We aimed to assess the efficacy of softer, second-generation hydrogel coils. METHODS: A randomized controlled trial was conducted at 22 centers in France and Germany. Patients aged 18 to 75 years with untreated ruptured or unruptured intracranial aneurysms measuring 4 to 12 mm in diameter were eligible and randomized (1:1 using a web-based system, stratified by rupture status) to coiling with either second-generation hydrogel coils or bare platinum coils. Assist devices were allowed as clinically required. Independent imaging core laboratory was masked to allocation. Primary end point was a composite outcome measure including major aneurysm recurrence, aneurysm retreatment, morbidity that prevented angiographic controls, and any death during treatment and follow-up. Data were analyzed as randomized. RESULTS: Randomization began on October 15, 2009, and stopped on January 31, 2014, after 513 patients (hydrogel, n=256; bare platinum, n=257); 20 patients were excluded for missing informed consent and 9 for treatment-related criteria. Four hundred eighty-four patients (hydrogel, n=243; bare platinum, n=241) were included in the analysis; 208 (43%) were treated for ruptured aneurysms. Final end point data were available for 456 patients. Forty-five out of 226 (19.9%) patients in the hydrogel group and 66/230 (28.7%) in the control group had an unfavorable composite primary outcome, giving a statistically significant reduction in the proportion of an unfavorable composite primary outcome with hydrogel coils-adjusted for rupture status-of 8.4% (95% confidence interval, 0.5-16.2; P=0.036). Adverse and serious adverse events were evenly distributed between groups. CONCLUSIONS: Our results suggest that endovascular coil embolization with second-generation hydrogel coils may reduce the rate of unfavorable outcome events in patients with small- and medium-sized intracranial aneurysms